Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Orthofix allograft

This article was originally published in The Gray Sheet

  • News

Executive Summary

Next-generation Trinity Evolution stem cell-based bone growth matrix will launch in June 2009, ahead of schedule, the firm announces Dec. 15. Orthofix inked a deal with the Musculoskeletal Transplant Foundation in August to develop Trinity Evolution, which is designed to mimic an autograft in spinal and orthopedic surgeries and is sourced from cadaver tissue (1"The Gray Sheet" Sept. 15, 2008, p. 11). The product will be the second stem cell-based allograft on the market after NuVasive's Osteocel, which Orthofix currently distributes as Trinity. NuVasive purchased Osteocel from Osiris Therapeutics in May, prompting Orthofix to pursue a replacement allograft

Table

View full table

Tags:
Latest Headlines

Valuable Health Data Sources For Medtech Industry Come A Step Closer In The EU

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

Discreet Gait Freezing Solution Brings Therapy With The Tap Of An Apple Watch

Shuren Says CDRH Is ‘Turning The Ship Around’ As Operations Return To Normal

See All
UsernamePublicRestriction

Register

MT026924

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By